Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy
Adalimumab (ADA), a monoclonal antibody targeting TNF-α, is effective in treating moderate to severe psoriasis. The emergence of biosimilars, such as GP2017 (Hyrimoz®), has raised concerns about their safety and efficacy compared to the originator. This two-year observational study evaluated the ef...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2025-07-01
|
| Series: | Dermatology Reports |
| Subjects: | |
| Online Access: | https://www.pagepress.org/journals/dr/article/view/10315 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849702401060110336 |
|---|---|
| author | Marco May Lee Vito Di Lernia Francesca Peccerillo Federico Bardazzi Michela Tabanelli Michela Ricci Davide Melandri Monica Corazza Francesca Satolli Andrea Conti |
| author_facet | Marco May Lee Vito Di Lernia Francesca Peccerillo Federico Bardazzi Michela Tabanelli Michela Ricci Davide Melandri Monica Corazza Francesca Satolli Andrea Conti |
| author_sort | Marco May Lee |
| collection | DOAJ |
| description |
Adalimumab (ADA), a monoclonal antibody targeting TNF-α, is effective in treating moderate to severe psoriasis. The emergence of biosimilars, such as GP2017 (Hyrimoz®), has raised concerns about their safety and efficacy compared to the originator. This two-year observational study evaluated the effectiveness and safety of GP2017 in 171 patients from Emilia-Romagna, Italy. Patients were divided into two groups: 78 transitioned from the ADA originator, and 93 were biologic-naive. Changes in the Psoriasis Area and Severity Index (PASI) were analyzed. In the switch group, PASI scores remained stable, while the naive group achieved significant improvements (PASI 75: 52% at 3 months, 89% at 6 months). Adverse events leading to discontinuation were rare. The findings confirm that GP2017 is as effective and safe as the ADA originator, supporting its use as a cost-effective alternative in the treatment of psoriasis. Biosimilars play a crucial role in promoting equitable access to biologic therapies.
|
| format | Article |
| id | doaj-art-33d3ab9bface48f8a86b3ccf6fa0fc37 |
| institution | DOAJ |
| issn | 2036-7392 2036-7406 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Dermatology Reports |
| spelling | doaj-art-33d3ab9bface48f8a86b3ccf6fa0fc372025-08-20T03:17:40ZengPAGEPress PublicationsDermatology Reports2036-73922036-74062025-07-0110.4081/dr.2025.10315Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, ItalyMarco May Lee0Vito Di Lernia1Francesca Peccerillo2Federico Bardazzi3Michela Tabanelli4Michela Ricci5Davide Melandri6Monica Corazza7Francesca Satolli8Andrea Conti9Private Practice, Dermatology, PaduaDermatologic Unit, Arcispedale Santa Maria Nuova, AUSL-IRCCS Reggio EmiliaDermatologic Unit, Arcispedale Santa Maria Nuova, AUSL-IRCCS Reggio EmiliaDermatologic Unit, IRCCS University Hospital of BolognaDermatologic Unit, AUSL Romagna, RavennaDermatologic Unit, AUSL Romagna, ForlìDermatologic Unit and Burn Center, AUSL Romagna, Bufalini Hospital, CesenaSection of Dermatology and Infectious Diseases, Department of Medical Sciences, University of FerraraSection of Dermatology, Department of Clinical and Experimental Medicine, University of ParmaDermatologic Unit, Department of Surgery, Infermi Hospital, AUSL Romagna, Rimini Adalimumab (ADA), a monoclonal antibody targeting TNF-α, is effective in treating moderate to severe psoriasis. The emergence of biosimilars, such as GP2017 (Hyrimoz®), has raised concerns about their safety and efficacy compared to the originator. This two-year observational study evaluated the effectiveness and safety of GP2017 in 171 patients from Emilia-Romagna, Italy. Patients were divided into two groups: 78 transitioned from the ADA originator, and 93 were biologic-naive. Changes in the Psoriasis Area and Severity Index (PASI) were analyzed. In the switch group, PASI scores remained stable, while the naive group achieved significant improvements (PASI 75: 52% at 3 months, 89% at 6 months). Adverse events leading to discontinuation were rare. The findings confirm that GP2017 is as effective and safe as the ADA originator, supporting its use as a cost-effective alternative in the treatment of psoriasis. Biosimilars play a crucial role in promoting equitable access to biologic therapies. https://www.pagepress.org/journals/dr/article/view/10315Psoriasisadalimumabbiosimilarsefficacysafety |
| spellingShingle | Marco May Lee Vito Di Lernia Francesca Peccerillo Federico Bardazzi Michela Tabanelli Michela Ricci Davide Melandri Monica Corazza Francesca Satolli Andrea Conti Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy Dermatology Reports Psoriasis adalimumab biosimilars efficacy safety |
| title | Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy |
| title_full | Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy |
| title_fullStr | Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy |
| title_full_unstemmed | Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy |
| title_short | Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy |
| title_sort | efficacy and safety of adalimumab biosimilar gp2017 in a 24 month treatment period for plaque psoriasis real life experience from emilia romagna centers italy |
| topic | Psoriasis adalimumab biosimilars efficacy safety |
| url | https://www.pagepress.org/journals/dr/article/view/10315 |
| work_keys_str_mv | AT marcomaylee efficacyandsafetyofadalimumabbiosimilargp2017ina24monthtreatmentperiodforplaquepsoriasisreallifeexperiencefromemiliaromagnacentersitaly AT vitodilernia efficacyandsafetyofadalimumabbiosimilargp2017ina24monthtreatmentperiodforplaquepsoriasisreallifeexperiencefromemiliaromagnacentersitaly AT francescapeccerillo efficacyandsafetyofadalimumabbiosimilargp2017ina24monthtreatmentperiodforplaquepsoriasisreallifeexperiencefromemiliaromagnacentersitaly AT federicobardazzi efficacyandsafetyofadalimumabbiosimilargp2017ina24monthtreatmentperiodforplaquepsoriasisreallifeexperiencefromemiliaromagnacentersitaly AT michelatabanelli efficacyandsafetyofadalimumabbiosimilargp2017ina24monthtreatmentperiodforplaquepsoriasisreallifeexperiencefromemiliaromagnacentersitaly AT michelaricci efficacyandsafetyofadalimumabbiosimilargp2017ina24monthtreatmentperiodforplaquepsoriasisreallifeexperiencefromemiliaromagnacentersitaly AT davidemelandri efficacyandsafetyofadalimumabbiosimilargp2017ina24monthtreatmentperiodforplaquepsoriasisreallifeexperiencefromemiliaromagnacentersitaly AT monicacorazza efficacyandsafetyofadalimumabbiosimilargp2017ina24monthtreatmentperiodforplaquepsoriasisreallifeexperiencefromemiliaromagnacentersitaly AT francescasatolli efficacyandsafetyofadalimumabbiosimilargp2017ina24monthtreatmentperiodforplaquepsoriasisreallifeexperiencefromemiliaromagnacentersitaly AT andreaconti efficacyandsafetyofadalimumabbiosimilargp2017ina24monthtreatmentperiodforplaquepsoriasisreallifeexperiencefromemiliaromagnacentersitaly |